{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T05:12:29Z","timestamp":1769836349755,"version":"3.49.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,6,28]],"date-time":"2013-06-28T00:00:00Z","timestamp":1372377600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1007\/s00280-013-2219-5","type":"journal-article","created":{"date-parts":[[2013,6,27]],"date-time":"2013-06-27T13:25:09Z","timestamp":1372339509000},"page":"453-461","source":"Crossref","is-referenced-by-count":10,"title":["Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab"],"prefix":"10.1007","volume":"72","author":[{"given":"Matthew D.","family":"Hellmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie E.","family":"Chaft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie","family":"Rusch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle S.","family":"Ginsberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Finley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark G.","family":"Kris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharine A. R.","family":"Price","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher. G.","family":"Azzoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew G.","family":"Fury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory J.","family":"Riely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee M.","family":"Krug","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Downey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manjit S.","family":"Bains","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camelia S.","family":"Sima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nabil","family":"Rizk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William D.","family":"Travis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naiyer A.","family":"Rizvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul K.","family":"Paik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,6,28]]},"reference":[{"key":"2219_CR1","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197108122850711","volume":"285","author":"J Folkman","year":"1971","unstructured":"Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182\u20131186","journal-title":"N Engl J Med"},{"key":"2219_CR2","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646\u2013674","journal-title":"Cell"},{"key":"2219_CR3","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/nm1101-1194","volume":"7","author":"D Lyden","year":"2001","unstructured":"Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig B, Marks W, Witte L, Wu Y, Hicklin D, Zhu Z, Hackett NR, Crystal RG, Moore MA, Hajjar KA, Manova K, Benezra R, Rafii S (2001) Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7:1194\u20131201","journal-title":"Nat Med"},{"key":"2219_CR4","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","volume":"9","author":"N Ferrara","year":"2003","unstructured":"Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669\u2013676","journal-title":"Nat Med"},{"key":"2219_CR5","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrc1093","volume":"3","author":"G Bergers","year":"2003","unstructured":"Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3:401\u2013410","journal-title":"Nat Rev Cancer"},{"key":"2219_CR6","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMra0706596","volume":"358","author":"RS Kerbel","year":"2008","unstructured":"Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358:2039\u20132049","journal-title":"N Engl J Med"},{"key":"2219_CR7","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nrm1911","volume":"7","author":"AK Olsson","year":"2006","unstructured":"Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L (2006) VEGF receptor signalling\u2014in control of vascular function. Nat Rev Mol Cell Biol 7:359\u2013371","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2219_CR8","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1200\/JCO.2011.40.4053","volume":"30","author":"PJ Koo","year":"2012","unstructured":"Koo PJ, Morgensztern D, Boyer JL, Herbst RS (2012) Targeting vascular endothelial growth factor in patients with squamous cell lung cancer. J Clin Oncol 30:1137\u20131139","journal-title":"J Clin Oncol"},{"key":"2219_CR9","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","volume":"355","author":"A Sandler","year":"2006","unstructured":"Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542\u20132550","journal-title":"N Engl J Med"},{"key":"2219_CR10","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1200\/JCO.2007.14.5466","volume":"27","author":"M Reck","year":"2009","unstructured":"Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27:1227\u20131234","journal-title":"J Clin Oncol"},{"key":"2219_CR11","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1200\/JCO.2004.11.022","volume":"22","author":"DH Johnson","year":"2004","unstructured":"Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF 3rd, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22:2184\u20132191","journal-title":"J Clin Oncol"},{"key":"2219_CR12","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S1470-2045(10)70151-0","volume":"11","author":"L Crino","year":"2010","unstructured":"Crino L, Dansin E, Garrido P, Griesinger F, Laskin J, Pavlakis N, Stroiakovski D, Thatcher N, Tsai CM, Wu YL, Zhou CC (2010) Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol 11:733\u2013740","journal-title":"Lancet Oncol"},{"key":"2219_CR13","first-page":"1318","volume":"20","author":"WF Novotny","year":"2001","unstructured":"Novotny WF, Holmgren E, Griffing S, Johnson D, De Vore R, Kabbinavar F (2001) Identification of squamous cell histology and central, cavitary tumors as possible risk factors for pulmonary hemorrhage (PH) in patients with advanced NSCLC receiving bevacizumab (BV). Proc Am Soc Clin Oncol 20:1318","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2219_CR14","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1200\/JCO.2008.16.2412","volume":"27","author":"AB Sandler","year":"2009","unstructured":"Sandler AB, Schiller JH, Gray R, Dimery I, Brahmer J, Samant M, Wang LI, Johnson DH (2009) Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab. J Clin Oncol 27:1405\u20131412","journal-title":"J Clin Oncol"},{"key":"2219_CR15","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/1097-0142(19800701)46:1<200::AID-CNCR2820460133>3.0.CO;2-V","volume":"46","author":"RR Miller","year":"1980","unstructured":"Miller RR, McGregor DH (1980) Hemorrhage from carcinoma of the lung. Cancer 46:200\u2013205","journal-title":"Cancer"},{"key":"2219_CR16","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1093\/annonc\/mdr463","volume":"23","author":"M Reck","year":"2012","unstructured":"Reck M, Barlesi F, Crino L, Henschke CI, Isla D, Stiebeler S, Spigel DR (2012) Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts. Ann Oncol 23:1111\u20131120","journal-title":"Ann Oncol"},{"key":"2219_CR17","doi-asserted-by":"crossref","unstructured":"Chaft JE, Rusch V, Ginsberg MS, Paik PK, Finley DJ, Kris MG, Price KAR, Azzoli CG, Fury MG, Riely GJ, Krug LM, Downey RJ, Bains MS, Sima CS, Rizk N, Travis WD, Rizvi NA\u00a0(2013) Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable non-squamous non-small cell lung cancers. J Thorac Oncol 8(8) (in press)","DOI":"10.1097\/JTO.0b013e31829923ec"},{"key":"2219_CR18","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1097\/JTO.0b013e31824c9485","volume":"7","author":"JE Chaft","year":"2012","unstructured":"Chaft JE, Rekhtman N, Ladanyi M, Riely GJ (2012) ALK-rearranged lung cancer: adenosquamous lung cancer masquerading as pure squamous carcinoma. J Thorac Oncol 7:768\u2013769","journal-title":"J Thorac Oncol"},{"key":"2219_CR19","unstructured":"Incorperated G (2011) Avastin (bevacizumab) intravenous infusion [package insert]. In: California SF (ed) http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/125085s225lbl.pdf"},{"key":"2219_CR20","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1200\/JCO.2011.38.9650","volume":"30","author":"JA Meyerhardt","year":"2012","unstructured":"Meyerhardt JA, Li L, Sanoff HK, Carpenter Wt, Schrag D (2012) Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer. J Clin Oncol 30:608\u2013615","journal-title":"J Clin Oncol"},{"key":"2219_CR21","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/JTO.0b013e3181f94ad4","volume":"6","author":"JD Hainsworth","year":"2011","unstructured":"Hainsworth JD, Fang L, Huang JE, Karlin D, Russell K, Faoro L, Azzoli C (2011) BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab\u00a0+\u00a0carboplatin\/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer. J Thorac Oncol 6:109\u2013114","journal-title":"J Thorac Oncol"},{"key":"2219_CR22","doi-asserted-by":"crossref","unstructured":"Scagliotti G, Novello S, von Pawel J, Reck M, Pereira JR, Thomas M, Abrao Miziara JE, Balint B, De Marinis F, Keller A, Aren O, Csollak M, Albert I, Barrios CH, Grossi F, Krzakowski M, Cupit L, Cihon F, Dimatteo S, Hanna N (2010) Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 28:1835\u20131842","DOI":"10.1200\/JCO.2009.26.1321"},{"key":"2219_CR23","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1200\/JCO.2011.41.4987","volume":"30","author":"GV Scagliotti","year":"2012","unstructured":"Scagliotti GV, Vynnychenko I, Park K, Ichinose Y, Kubota K, Blackhall F, Pirker R, Galiulin R, Ciuleanu TE, Sydorenko O, Dediu M, Papai-Szekely Z, Banaclocha NM, McCoy S, Yao B, Hei YJ, Galimi F, Spigel DR (2012) International, randomized, placebo-controlled, double-blind phase III study of Motesanib Plus Carboplatin\/Paclitaxel in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer: MONET1. J Clin Oncol 30:2829\u20132836","journal-title":"J Clin Oncol"},{"key":"2219_CR24","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(10)70132-7","volume":"11","author":"RS Herbst","year":"2010","unstructured":"Herbst RS, Sun Y, Eberhardt WE, Germonpre P, Saijo N, Zhou C, Wang J, Li L, Kabbinavar F, Ichinose Y, Qin S, Zhang L, Biesma B, Heymach JV, Langmuir P, Kennedy SJ, Tada H, Johnson BE (2010) Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 11:619\u2013626","journal-title":"Lancet Oncol"},{"key":"2219_CR25","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1200\/JCO.2010.29.5717","volume":"29","author":"RH Boer de","year":"2011","unstructured":"de Boer RH, Arrieta O, Yang CH, Gottfried M, Chan V, Raats J, de Marinis F, Abratt RP, Wolf J, Blackhall FH, Langmuir P, Milenkova T, Read J, Vansteenkiste JF (2011) Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol 29:1067\u20131074","journal-title":"J Clin Oncol"},{"key":"2219_CR26","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1200\/JCO.2010.28.5981","volume":"29","author":"RB Natale","year":"2011","unstructured":"Natale RB, Thongprasert S, Greco FA, Thomas M, Tsai CM, Sunpaweravong P, Ferry D, Mulatero C, Whorf R, Thompson J, Barlesi F, Langmuir P, Gogov S, Rowbottom JA, Goss GD (2011) Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 29:1059\u20131066","journal-title":"J Clin Oncol"},{"key":"2219_CR27","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1200\/JCO.2011.36.1709","volume":"30","author":"JS Lee","year":"2012","unstructured":"Lee JS, Hirsh V, Park K, Qin S, Blajman CR, Perng RP, Chen YM, Emerson L, Langmuir P, Manegold C (2012) Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 30:1114\u20131121","journal-title":"J Clin Oncol"},{"key":"2219_CR28","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1200\/JCO.2009.22.9427","volume":"28","author":"GD Goss","year":"2010","unstructured":"Goss GD, Arnold A, Shepherd FA, Dediu M, Ciuleanu TE, Fenton D, Zukin M, Walde D, Laberge F, Vincent MD, Ellis PM, Laurie SA, Ding K, Frymire E, Gauthier I, Leighl NB, Ho C, Noble J, Lee CW, Seymour L (2010) Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol 28:49\u201355","journal-title":"J Clin Oncol"},{"key":"2219_CR29","doi-asserted-by":"crossref","unstructured":"Laurie SA, Solomon BJ, Seymour L, Ellis PM, Goss GD, Shepherd FA, Boyer MJ, Arnold AM, Clingan P, Laberge F, Fenton D, Hirsh V, Zukin M, Stockler MR, Lee CW, Chen EX, Montenegro A, Ding K, Bradbury PA, Group NCT (2012) A randomized double-blind trial of carboplatin plus paclitaxel (CP) with daily oral cediranib (CED), an inhibitor of vascular endothelial growth factor receptors, or placebo (PLA) in patients (pts) with previously untreated advanced non-small cell lung cancer (NSCLC): NCIC Clinical Trials Group study BR29. J Clin Oncol 30(suppl):7511","DOI":"10.1200\/jco.2012.30.15_suppl.7511"},{"key":"2219_CR30","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0022-5223(98)70398-8","volume":"115","author":"H Imoto","year":"1998","unstructured":"Imoto H, Osaki T, Taga S, Ohgami A, Ichiyoshi Y, Yasumoto K (1998) Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma. J Thorac Cardiovasc Surg 115:1007\u20131014","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2219_CR31","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/(SICI)1097-0215(19970220)74:1<64::AID-IJC11>3.0.CO;2-I","volume":"74","author":"M Volm","year":"1997","unstructured":"Volm M, Koomagi R, Mattern J (1997) Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int J Cancer 74:64\u201368","journal-title":"Int J Cancer"},{"key":"2219_CR32","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1097\/JTO.0b013e3181a97e31","volume":"4","author":"P Zhan","year":"2009","unstructured":"Zhan P, Wang J, Lv XJ, Wang Q, Qiu LX, Lin XQ, Yu LK, Song Y (2009) Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis. J Thorac Oncol 4:1094\u20131103","journal-title":"J Thorac Oncol"},{"key":"2219_CR33","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1200\/JCO.2011.37.4231","volume":"30","author":"MJ Pajares","year":"2012","unstructured":"Pajares MJ, Agorreta J, Larrayoz M, Vesin A, Ezponda T, Zudaire I, Torre W, Lozano MD, Brambilla E, Brambilla C, Wistuba II, Behrens C, Timsit JF, Pio R, Field JK, Montuenga LM (2012) Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung. J Clin Oncol 30:1129\u20131136","journal-title":"J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2219-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-013-2219-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2219-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T06:19:34Z","timestamp":1596003574000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-013-2219-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,28]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["2219"],"URL":"https:\/\/doi.org\/10.1007\/s00280-013-2219-5","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,28]]}}}